Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2010-07-26 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations release announcing the launch of a generic version of Lovenox by Sandoz, a division of Novartis. It includes forward-looking statements, product information, and contact details. There are no financial statements or detailed financial analysis present. The document is an announcement of a corporate event (product launch and FDA approval) rather than a financial report or earnings release. It does not fit into categories like Annual Report, Earnings Release, or Interim Report. It is a regulatory filing providing material information to investors and the SEC but does not contain financial data or management discussion. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (9224 characters) is sufficient to be a full filing, not just a brief announcement, but the content is clearly a regulatory announcement rather than a financial report.
2010-07-26 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing regulatory approval in China for a drug called Rasilez. It contains no financial statements or detailed financial analysis but rather a corporate announcement about product approval and market information. The document length is about 13,911 characters, which is substantial but the content is clearly a press release rather than a financial report. There is no indication of quarterly or annual financial results, audit information, or management discussion of financial performance. The document is not a report publication announcement since it contains the full text of the press release. Given these factors, the filing best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and press releases that do not fit other categories.
2010-07-21 English
Regulatory Filings 2010
Regulatory Filings
2010-07-20 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content includes detailed financial performance data for the second quarter and first half of 2010, including net sales, operating income, EPS, and core operating income. It also contains management commentary on the results, strategic priorities, and product pipeline updates. The document is about 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The detailed financial data and management discussion align with the characteristics of an Interim / Quarterly Report. Form 6-K is commonly used by foreign private issuers to report quarterly financial results and other material information. Therefore, the document should be classified as an Interim / Quarterly Report (IR).
2010-07-20 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content focuses on an investor relations release about a settlement agreement resolving gender discrimination claims, including monetary payments and policy changes. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is primarily a regulatory announcement about legal settlement and corporate policy changes, not a financial report or earnings release. It is not a certification or attestation letter either. Given the nature of the content and the form type (6-K), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2010-07-20 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content includes detailed financial performance data for the second quarter and first half of 2010, including net sales, operating income, EPS, and core operating income. It also discusses business highlights, innovation, product approvals, and strategic priorities. The document contains substantive financial data and analysis for a period shorter than a full fiscal year (quarterly and half-year results). This matches the definition of an Interim / Quarterly Report (IR). The document is not merely an announcement or a certification but a comprehensive financial report for a period shorter than a full fiscal year.
2010-07-15 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.